SUMMARY: The Food and Drug Administration is announcing the availability of a guidance for industry entitled "Botanical Drug Development." This guidance describes FDA's current thinking on appropriate development plans for botanical drugs to be submitted in new drug applications and specific recommendations for submitting investigational new drug..
Dannex Limited, a manufacturer and distributor of pharmaceutical products, has acquired a 53.47% stake in Ayrton Drug Manufacturing Limited, a manufacturer and seller of pharmaceutical and healthcare products, from Adcock Ingram Holdings, Ltd. Dannex and Ayrton are based in Ghana. Adcock is a manufacturer, marketer and distributor of a range of hea
PROVECTUS BIOPHARMACEUTICALS, INC. (OTCMKTS:PVCT) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Item5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Ce
When I was younger, my friends warned me that if I drank expired cough syrup, my teeth would fall out. Today, I can proudly say my teeth remained intact, but it does bring up the question: What happens when we use expired medicine? The concept of expiration dates on medicines was introduced in 1979 by the U.S. Food and Drug Administration to help c
Nutra Pharma Corporation, a biotechnology company marketing Nyloxin and Pet Pain-Away? in the over-the-counter pain management market, and which is also developing treatments for Multiple Sclerosis, Human Immunodeficiency Virus, Adrenomyeloneuropathy and Pain announced today that the Company s Chief Executive Officer, Rik J Deitsch, has pub
Some of Indias largest drug makers such as Sun Pharmaceuticals Industries Ltd, Dr Reddys Laboratories Ltd and Glenmark Pharmaceuticals Ltd are creating a portfolio of over-the-counter products. In India, there are a lot of regulations on prescription drugs but consumer healthcare offers a slightly more positive and open environment, especially on t
SUMMARY: The Food and Drug Administration is amending the animal drug regulations to reflect approval of 71 supplemental new animal drug applications and 35 supplemental abbreviated new animal drug applications for revised labeling reflecting a change in marketing status from over-the-counter use to use by veterinary feed directive for...
Nutra Pharma Corporation, a biotechnology company marketing Nyloxin and Pet Pain-Away? in the over-the-counter pain management market, and which is also developing treatments for Multiple Sclerosis, Human Immunodeficiency Virus, Adrenomyeloneuropathy and Pain announced today that the Company's Chief Executive Officer, Rik J Deitsch, has publis
SUMMARY: The Food and Drug Administration is amending the animal drug regulations to reflect approval of 43 supplemental new animal drug applications and 52 supplemental abbreviated new animal drug applications for revised labeling reflecting a change in marketing status from over-the-counter to prescription for antimicrobial drugs of importance...
Purdue Pharma and Exicure Announce Strategic Research Collaboration Agreement to Discover and Develop a Treatment for Psoriasis and Other Diseases Utilizing SNA? Technology. By a News Reporter-Staff News Editor at Pharma Business Week Purdue Pharma L.P. and Exicure, Inc. announced a strategic research collaboration, option and license agreement
The U.S. Food and Drug Administration has issued the Veterinary Feed Directive rule, or VFD, which requires a licensed veterinarian to write a statement authorizing the use of certain drugs in food animal feed before a producer can obtain it. It's part of the FDA's effort to address antibiotic resistance and phase out the use of medically important
The acquisition will be structured as an all-stock deal with both companies contributing equity interests into a newly created trust, resulting in Vitel operating as a wholly owned subsidiary of OncBioMune, according to documents filed with the U.S. Securities and Exchange Commission. OncBioMune President and Chief Financial Officer Andrew Kucharch
Dipexium Pharmaceuticals, Inc. and PLx Pharma Inc., a privately held late-stage specialty pharmaceutical company, announced today that they have entered into a definitive agreement under which PLx Pharma will merge with a wholly-owned subsidiary of Dipexium in an all-stock transaction. Following closing, Dipexium will be renamed PLx Pharma Inc., an
Reals Pharmaceutical Ltd, a leading pharmaceutical company has introduced Reals Night Aid, a new non habit forming, over- the- counter sleep aid for the relief of occasional sleeplessness. The new OTC drug which was formally presented to the public at the 89th Annual Pharmaceutical Society of Nigeria conference in Minna, Niger State, enables users
ChemoCentryx to retain commercialization rights in the United States and China, Vifor Pharma gains rights in all other markets ChemoCentryx to receive upfront cash commitment of USD 50 million plus potential milestones and royalties Vifor Pharma receives an option to develop and commercialize CCX140 in chronic kidney disease with U.S
CURE Pharmaceutical, a preeminent developer and manufacturer of advanced oral thin film for use in pharmaceutical, veterinary, and buccal and dermal over-the-counter applications, today announces it has appointed William Yuan and Charles Berman to its Board of Directors. Both William and Charles add tremendous depth and experience in their ind
NEW YORK and HOUSTON, Dec. 22, 2016/ PRNewswire/ Dipexium Pharmaceuticals, Inc. and PLx Pharma Inc., a privately held late-stage specialty pharmaceutical company, announced today that they have entered into a definitive agreement under which PLx Pharma will merge with a wholly-owned subsidiary of Dipexium in an all-stock transaction. Following cl
Dec. 21 At the end of a year that saw a person die every day, on average, from drug overdoses in Maine, it is encouraging that the LePage administration is increasing its support of medicine-assisted treatment, which research has shown to be the most effective method to address substance use disorder. On Tuesday, the Maine Department of Health an
Endo International plc announced today that it has appointed Patrick Barry as Senior Vice President, U.S. Branded Pharmaceuticals, effective immediately; and Matthew Davis, M.D., R.Ph., as Senior Vice President, Research and Development Branded Pharmaceuticals, effective January 3, 2017. In his new position, Mr. Barry will have responsibility for
Novartis announced today that it has signed a licensing agreement with Sunovion Pharmaceuticals Inc. for the US commercial rights to its three treatments for chronic obstructive pulmonary disease, Utibron? Neohaler inhalation powder, Seebri? Neohaler inhalation powder, and Arcapta Neohaler inhalation powder. This deal is specific
Dubai: A senior Dubai Health Authority official on Sunday warned residents not to take any medicine without a doctor's prescription. Dr Ali Al Sayed, director of the DHA's pharmaceutical services department, said that to get the maximum benefit from medication, it is important to take it exactly as prescribed by the doctor. With the change in weath
In today's pre-market research, Stock-Callers.com monitors the most recent performances of four major players in the Drug Manufacturers space, namely: Bristol-Myers Squibb Co., AstraZeneca PLC, Eli Lilly and Co., and GlaxoSmithKline PLC. New York headquartered Bristol-Myers Squibb Co.' s shares rose 1.36%, closing Monday's trading session at $59.42
The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. The report profiles 113 companies including many key and niche players such as- Bayer HealthCare AG Boehringer Ingelheim GmbH Ceva Sant Animale S.A Dechra Pharmaceuticals PLC Eli Lilly and Company Download the fu
CURE Pharmaceutical, a preeminent developer and manufacturer of advanced oral thin film for use in pharmaceutical, veterinary, and buccal and dermal over-the-counter applications, announces today the completion of a going public transaction and the issuance of its new stock symbol- CURR. After nearly six years of intense R&D activities, CURE..
-Parnell Pharmaceuticals Holdings Ltd, a fully integrated, commercial-stage pharmaceutical company focused on developing, manufacturing and marketing innovative animal health solutions, today announced that it will file a Form 25, Notification of Removal from Listing and/or Registration under Section 12 of the Securities Exchange Act, with the...